Ted Bird

Chief Strategy Officer, Dymicron

Ted Bird has over 35 years of global commercial and executive leadership experience in the medical device industry. Ted is currently Chief Strategy Officer with Dymicron, a pre-commercial startup with a breakthrough next generation artificial cervical disc and Principal of Bird Medical Group, a strategic management consulting and go-to-market Medtech commercialization solutions provider. Ted is also currently on the Board of Novum Medical, a pre-commercial startup company with a proprietary bio-regenerative material for implantable musculoskeletal devices. He was previously the Chief Commercial Officer for Titan Spine, helping them achieve market-leading growth in the interbody spine fusion segment with a unique nano-textured titanium surface technology prior to an acquisition by Medtronic. Ted also served as Chairman of the Board for ApiFix, Ltd., a commercial stage Israeli startup company with a novel fusionless minimally invasive treatment alternative for Adolescent Idiopathic Scoliosis (AIS). ApiFix was acquired by Orthopediatrics in 2020. Mr. Bird also held key executive and management leadership positions at Orthofix, Depuy Spine, Medtronic Sofamor Danek, Johnson & Johnson Orthopedics, Microvasive, (Division of Boston Scientific) and Dyonics, (now Smith & Nephew). Ted graduated from Brown University in Providence, RI with Bachelor’s Degrees in International Relations and Political Science.